# Nuvectis Pharma, Inc.: Form 8-K, filed Feb 4, 2022

- Company: [Nuvectis Pharma, Inc.](/companies/nvct.md) (CIK 1875558)
- Form: 8-K
- Filed: 2022-02-04
- Accepted by EDGAR: Feb 4, 2022, 10:20 ET
- Period: 2022-02-04
- Accession: 0001104659-22-011786
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 5.03: Amendment to articles or bylaws
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_8k.htm

Filed Feb 4, 2022.
Source: SEC EDGAR, the filing index for accession 0001104659-22-011786. Last ingested by Listed: Nov 4, 2026, 08:08 ET. No prices; not investment advice.
